Linked Data API

Show Search Form

Search Results

registered interest false remove filter
date less than 2019-05-08more like thismore than 2019-05-08
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Pneumococcal Diseases: Vaccination more like this
house id 2 more like this
pref label House of Lords more like this
question text To ask Her Majesty's Government what assessment they have made of the recommendations by the Joint Committee on Vaccination and Immunisation to reduce the infant pneumococcal vaccination schedule from three doses to two. more like this
tabling member printed
Baroness Masham of Ilton remove filter
uin HL15599 remove filter
is ministerial correction false more like this
date of answer less than 2019-05-22more like thismore than 2019-05-22
answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p>
answering member printed Baroness Blackwood of North Oxford more like this
grouped question UIN HL15600 more like this
question first answered
less than 2019-05-22T14:50:14.54Zmore like thismore than 2019-05-22T14:50:14.54Z
answering member
label Biography information for Baroness Blackwood of North Oxford more like this
file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf more like this
title JCVI Minute 2015 more like this
tabling member
label Biography information for Baroness Masham of Ilton more like this